Cyprotex Discovery Receives French Research Tax Credit Accreditation
Cyprotex (AIM:CRX), the drug discovery technology and information company, is pleased to announce that it has received French research tax credit approval for years 2009 through to 2011.
The French Ministry of Research (Ministère de l'Enseignement Supérieur et de la Recherche) has granted the French R&D tax credit ("Crédit d'Impôt Recherche", CIR) accreditation to Cyprotex as of March 2010. This initiative allows eligible French pharmaceutical, biotech and agricultural companies subject to corporate tax in France, the ability to claim significant tax relief on costs generated in R&D requirements that are outsourced to Cyprotex Discovery.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: 'We are delighted to receive this recognition and approval from the French Ministry of Research which will provide greater opportunities to support our current client base and allow for improved collaborations with future French clients.'
Additional information on the French research tax credit system is available from the Ministère de l'Enseignement Supérieur et de la Recherche site - http://www.enseignementsup-recherche.gouv.fr/
Execution Noble & Company Limited
Tel: 020 7456 9191
Tel: 020 7831 3113